Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (639)	4/22/1998 2:21:00 PM
From: one putt	Read Replies (2) \| Respond to of 1491

Just read this in Yahoo! Wednesday April 22, 1:51 pm Eastern Time Company Press Release SOURCE: Pharmos Corporation Pharmos Announces New Data Demonstrating the Value of Lotemax(TM) in Treating Postcataract Surgery Inflammation Bausch & Lomb to Launch Lotemax(TM) ISELIN, N.J., April 22 /PRNewswire/ -- Pharmos Corporation (Nasdaq: PARS - news) and Bausch & Lomb Pharmaceuticals presented new data at the American Society of Cataract and Refractive Surgery, showing that Lotemax(TM) (loteprednol etabonate ophthalmic suspension 0.5%) offers clinically meaningful reduction in the signs and symptoms of cataract postoperative anterior chamber inflammation when compared to placebo. Bausch & Lomb also announced that Lotemax will be available to physicians and in retail pharmacies by June 1, 1998. This new study was designed to assess the activity of Lotemax dosed one drop into the operated eye four times a day for 14 days in treating inflammation in patients after cataract surgery with intraocular lens implantation. According to the results, presented by Ellen Strahlman, MD, MHSc, vice president of Corporate Medical and Scientific Affairs for Bausch & Lomb, Lotemax showed a clinical and statistically significant difference over its placebo vehicle in the treatment of postoperative inflammation. The proportion of patients with anterior chamber inflammation completely resolved by the final visit was 64% in the Lotemax group and 29% in the placebo group. In addition, anterior chamber inflammation was resolved or mild in 89% of Lotemax patients by their final visit. Also, for other signs and symptoms, the resolution rate and mean change from baseline favored Lotemax. There was no evidence of rebound signs after cessation of therapy, and the safety profile of Lotemax was excellent, with little evidence of clinically significant elevations in intraocular pressure or deleterious effects on postoperative recovery. Lotemax, approved on March 10, 1998 is a topical, site-specific steroid that will be used to treat steroid-responsive inflammatory conditions and postoperative inflammation of the eye. The novel chemical structure of Lotemax allows it to be predictably transformed by enzymes in the eye to an inactive metabolite, and increases its safety profile. The excellent safety profile of Lotemax was demonstrated in clinical trials by a low incidence of increased intraocular pressure, a significant side effect of ophthalmic steroid use. In addition to the excellent safety profile of Lotemax, the product will have the broadest range of indications of any ophthalmic steroid on the market. ''This presentation at the American Society of Cataract and Refractive Surgery is significant and shows Bausch & Lomb's commitment to the successful launch of Lotemax,'' stated Dr. Haim Aviv, Chairman and CEO of Pharmos Corporation. Pharmos co-developed Lotemax with Bausch & Lomb after Pharmos granted the global eye-care company the rights to manufacture and market the new ophthalmic pharmaceutical line in June 1995. In December 1996, Bausch & Lomb's rights were extended to selected international markets including Europe and Canada. Pharmos Corporation is a biopharmaceutical company engaged in the design, development, and commercialization of proprietary products to treat ophthalmic and neurological disorders. The news release contains forward-looking statements that involve risk and uncertainties. The development of the company's products may differ materially from the company's expectations. Among the factors that could result in a materially different outcome are the inherent uncertainties accompanying new product development, actions of regulatory authorities and the results of further trials. SOURCE: Pharmos Corporation Craig~